Analysis of Drug and Administrative Costs Allowed by U.S. Private and Public Third-Party Payers for 3 Intravenous Biologic Agents for Rheumatoid Arthritis

por Stavrakas, Spyros, Wong, Bruce, Cifaldi, Mary A., Roy, Sanjoy, Skonieczny, Dean
Publicado 2011

Modelling the cost-effectiveness of combination therapy for early, rapidly progressing rheumatoid arthritis by simulating the reversible and irreversible effects of the disease

por Stephens, Stephanie, Botteman, Marc F, Cifaldi, Mary A, van Hout, Ben A
Publicado 2015

Biologic TNF inhibiting agents for treatment of rheumatoid arthritis: persistence and dosing patterns in Germany

por Neubauer, Sarah, Cifaldi, Mary, Mittendorf, Thomas, Ganguli, Arijit, Wolff, Malte, Zeidler, Jan
Publicado 2014

Association of joint space narrowing with impairment of physical function and work ability in patients with early rheumatoid arthritis: protection beyond disease control by adalimu...

por Smolen, Josef S, van der Heijde, Désirée M, Keystone, Edward C, van Vollenhoven, Ronald F, Goldring, Mary B, Guérette, Benoît, Cifaldi, Mary A, Chen, Naijun, Liu, Shufang, Landewé, Robert B M
Publicado 2013